Emerging Research in the Chronic Lymphocytic Leukemia Space

Alexey Danilov, MD, PhD, provides an overview on the recent updates and research in the chronic lymphocytic leukemia space.

Alexey Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center, and professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, provides an overview on the recent updates and research in the chronic lymphocytic leukemia (CLL) space.

In this field, experts have their choice of treatment options, including Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax (Venclexta).

With the introduction of these targeted agents, there has been a significant reduction in the of use of chemoimmunotherapy regimens for this patient population.


Transcription:

0:08 | [There are] some targeted therapies which are emerging, some interesting novel antibodies, we have several trials which are exploiting tafasitamab-cxix [Monjuvi], a CD19 targeting antibody in chronic lymphocytic leukemia, and there is also a novel class of agents called cyclin dependent kinase 9 inhibitors.

0:30 | There are several agents being explored there in CLL which targets an anti-apoptotic protein, MCL-1. There are also some immune therapies and cellular therapy approaches in addition to CAR T cells. There are also CAR NK cells which have some very interesting data in CLL, but it is very early data.